| Date | Time | Source | |
| 06/11/2012 | 6:19PM | DJN | BioMed to Acquire UK's Granta Park for $196 Million
By Nathalie Tadena BioMed Realty Trust Inc. (BMR) has agreed to acquire Granta Park, a life-science research park in Cambridge, England, for approximately 126.8 million pounds, or $196 million, as the real-estate investment trust continues to grow its portfolio in large research markets. "The Cambridge market enjoys all... More...>> |
| 12/05/2011 | 6:12PM | PRNUS | S&P Indices Announces Changes to U.S. Indices
S&P Indices Announces Changes to U.S. Indices PR Newswire NEW YORK, Dec. 5, 2011 NEW YORK, Dec. 5, 2011 /PRNewswire/ -- S&P SmallCap 600 constituent National Retail Properties Inc. (NYSE: NNN) will replace Pharmaceutical Product Development Inc. (NASD: PPDI) in the S&P MidCap 400 index, and Higher One Holdings Inc. (NYSE:... More...>> |
| 12/05/2011 | 3:26PM | BW | The Carlyle Group and Hellman & Friedman Complete Acquisition of PPD
Pharmaceutical Product Development, Inc. today announced the completion of its acquisition by affiliates of The Carlyle Group and affiliates of Hellman & Friedman in an all-cash transaction valued at approximately $3.9 billion. As previously announced, the transaction was approved by PPD shareholders at a special meeting... More...>> |
| 12/02/2011 | 6:00AM | ZACKS | PPDI Shareholders Nod to Merger - Analyst Blog
Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman & Friedman. The merger was announced in October 2011. PPD shareholders have been offered a cash consideration... More...>> |
| 11/30/2011 | 2:00PM | BW | PPD Announces Shareholder Approval of Merger with Affiliates of The Carlyle Group and Hellman & Friedman
Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced that its shareholders have voted to approve the adoption of the agreement and plan of merger, dated October 2, 2011, providing for the merger of the company with an entity controlled by affiliates of The Carlyle Group and affiliates of Hellman & Friedman... More...>> |
| 11/16/2011 | 3:30AM | ZACKS | VirtualScopics Beats by a Whisker - Analyst Blog
Medical imaging solutions provider VirtualScopics’ (VSCP) third-quarter 2011 earnings of 2 cents a share beat the Zacks Consensus Estimate by a penny while matching the year-ago earnings. The New York-based company’s net income (attributable to common stockholders) clipped roughly 10.5% year over year to $562,926... More...>> |
| 11/04/2011 | 9:30AM | BW | PPD Named Best Contract Research Organization and Honored for Best Technological Development in Clinical Trials by Scrip
Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced it has been named the best contract research organization by Scrip Intelligence, which also has honored PPD for deploying the best technological development in clinical trials. Scrip presented both awards to PPD at the seventh annual Scrip Awards ceremony... More...>> |
| 11/02/2011 | 8:25AM | BW | PPD Declares Fourth Quarter Dividend
Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced that its board of directors declared a cash dividend for the fourth quarter of 2011 under its annual cash dividend policy. The quarterly cash dividend will equal $0.15 per share. The record date for the fourth quarter dividend is 5:00 p.m. Eastern... More...>> |
| 11/02/2011 | 8:02AM | BW | PPD Announces End of “Go-Shop” Period and Early Termination of Hart-Scott-Rodino Waiting Period
Pharmaceutical Product Development, Inc. (Nasdaq: PPDI) today announced the expiration of the 30-day “go-shop” period pursuant to the terms of the previously announced definitive merger agreement, entered into on October 2, 2011, between PPD and affiliates of The Carlyle Group and affiliates of Hellman & Friedman LLC... More...>> |
| 11/01/2011 | 8:10AM | MWUS | Equity Research on Pharmaceutical Product Development Inc. and Quest Diagnostics Inc. - Acquisitions and Privatizations Domin...
www.shinesrooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Medical Laboratories & Research industry and are offering free analytical research on Pharmaceutical Product Development Inc. (NASDAQ: PPDI... More...>> |
| 10/27/2011 | 9:48AM | BW | Bull & Lifshitz, LLP Announces Investigation of Pharmaceutical Product Development, Inc.
Bull & Lifshitz, LLP announces an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) (referred to as "PPD" or the “Company”) to affiliates of The Carlyle Group ("Carlyle") and Hellman & Friedman LP (“Hellman & Friedman”... More...>> |
| 10/20/2011 | 9:00AM | MWUS | What's Ahead: Today's Economic Outlook - Equity Research on Human Genome Sciences and Pharmaceutical Product Development, Inc.
Today, www.EquityMarketsInc.com announced its research report highlighting Human Genome Sciences (NASDAQ: HGSI) and Pharmaceutical Product Development, Inc. (NASDAQ: PPDI). Full content and research is available at www.EquityMarketsInc.com/research.php?id=HGSI+PPDI. Short-term outlooks within US and global economies continue... More...>> |
| 10/13/2011 | 2:11PM | BW | PPD Announces 2011 PPD Beach2Battleship Triathlon Heroes
PPD, Inc. (Nasdaq: PPDI) today announced the 2011 PPD Heroes team, featuring cancer survivors and medical specialists competing as triathletes in the PPD Beach2Battleship Triathlon on Oct. 29. The PPD Heroes are helping raise public awareness about the value of participating in clinical trials in the development of life-changing... More...>> |
| 10/07/2011 | 2:02PM | BW | Law Offices of Howard G. Smith LLP Continues Investigation of Pharmaceutical Product Development, Inc.
Law Offices of Howard G. Smith is continuing its investigation of potential claims against the Board of Directors of Pharmaceutical Product Development, Inc. (“PPD” or the “Company”) (NASDAQ:PPDI) related to the proposed acquisition of the Company to an affiliate of The Carlyle Group and Hellman & Friedman. The... More...>> |
| 10/07/2011 | 5:15AM | ZACKS | PPDI to Go Private - Analyst Blog
Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that it has entered into an agreement to be acquired by privately held The Carlyle Group and Hellman & Friedman for $3.9 billion in cash. PPD shareholders have been offered a cash consideration of $33.25 per share... More...>> |
| 10/05/2011 | 5:30PM | BW | MURRAY FRANK LLP Announces Investigation of Pharmaceutical Product Development, Inc.
MURRAY FRANK LLP is investigating claims of breach of fiduciary duties by certain members of the board of directors of Pharmaceutical Product Development, Inc. (NYSE: PPDI) (“PPD” or the “Company”) in relation to the acquisition of the Company by private equity firms Carlyle Group (“Carlyle”) and Hellman... More...>> |
| 10/05/2011 | 1:40PM | BW | Robbins Umeda LLP Announces an Investigation of Pharmaceutical Product Development, Inc.
Robbins Umeda LLP, a shareholder rights litigation firm, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the board of directors of Pharmaceutical Product Development, Inc. ("PPD") (NASDAQ: PPDI) in connection with their efforts to sell the company... More...>> |
| 10/04/2011 | 7:00PM | BW | Faruqi & Faruqi, LLP Announces Investigation of Pharmaceutical Product Development Inc.
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Pharmaceutical Product Development Inc. (“PPD” or the “Company”) (NASDAQ: PPDI) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the... More...>> |
| 10/04/2011 | 6:03PM | BW | Ryan & Maniskas, LLP Announces Investigation of Pharmaceutical Product Development Inc.
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/ppdi) is investigating potential claims against the board of directors of Pharmaceutical Product Development Inc. ("PPD" or the "Company") (NASDAQ: PPDI) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell PPD... More...>> |
| 10/04/2011 | 4:01PM | PRNUS | Investigation of Pharmaceutical Product Development by Securities Lawyers at Goldfarb Branham Law Firm LLP for Potential Shar...
Investigation of Pharmaceutical Product Development by Securities Lawyers at Goldfarb Branham Law Firm LLP for Potential Shareholder Claim Due to Buyout PR Newswire DALLAS, Oct. 4, 2011 DALLAS, Oct. 4, 2011 /PRNewswire/ -- Goldfarb Branham LLP is investigating whether the board of directors of Pharmaceutical Product Development... More...>> |
